Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism

Thrombosis Journal

Volumn 9, Issue , 2011, Pages

  Fareed, Jawed ^a   Adiguzel, Cafer ^a,b   Thethi, Indermohan ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Aurora Memorial Hospital of Burlington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; RIVAROXABAN; TINZAPARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER TOXICITY; OSTEOPENIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 79953093818     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-9-5     Document Type: Review

References (68)

1. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162:1245-1248. 10.1001/archinte.162.11.1245, 12038942.
2. Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007, 82:777-782. 10.1002/ajh.20983, 17626254.
3. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007, 167:1471-1475. 10.1001/archinte.167.14.1471, 2762787, 17646600.
4. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
5. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488. 10.1182/blood-2002-01-0108, 12393647.
6. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, . American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):381S-453S. 10.1378/chest.08-0656, 18574271, American College of Chest Physicians.
7. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, . American College of Chest Physicians Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):454S-545S. 10.1378/chest.08-0658, 18574272, American College of Chest Physicians.
8. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006, 25:101-161. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie.
9. Nightingale SL. From the Food and Drug Administration. JAMA 1993, 270:1672. 10.1001/jama.270.14.1672, 8411485.
10. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2004 Writing Committee Members 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329. 10.1161/CIRCULATIONAHA.107.188209, 18071078, 2004 Writing Committee Members.
11. Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Human Use (CHMP)., http://www.emea.europa.eu/pdfs/human/biosimilar/11826407en.pdf
12. World Health Organization World Health Organization., http://www.who.int/biologicals/areas/biological_therapeutics/Final%20Biosimilar%20meeting%20Report%20for%20web%2013%20September%202007.pdf
13. Kakkar W, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993, 341:259-265. 10.1016/0140-6736(93)92614-Y, 8093915.
14. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, . American College of Chest Physicians Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):141S-159S. 10.1378/chest.08-0689, 18574264, American College of Chest Physicians.
15. Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-4205.
16. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002, 11:397-407. 10.1517/13543784.11.3.397, 11866668.
17. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D, Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000, 83:14-19.
18. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001, 88:913-930. 10.1046/j.0007-1323.2001.01800.x, 11442521.
19. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929. 10.1056/NEJM198610093151503, 3531851.
20. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, Jay RM, Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991, 114:545-551.
21. Colwell CW, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994, 76:3-14.
22. Colwell CW, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999, 81:932-940. 10.1302/0301-620X.81B5.10316, 10428124.
23. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199-2207. 10.1001/archinte.160.14.2199, 10904464.
24. Planès A, Samama MM, Lensing AW, Büller HR, Barre J, Vochelle N, Beau B. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999, 81:22-25.
25. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, . European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-1720. 10.1016/S0140-6736(02)08652-X, 12049858, European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee.
26. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, . PENTATHALON 2000 Study Steering Committee Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-1726. 10.1016/S0140-6736(02)08648-8, 12049860, PENTATHALON 2000 Study Steering Committee.
27. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996, 124:619-626.
28. Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner GA, Whitsett TL, O'Connell MB, Ohar JA, Young TR, . Enoxaparin Clinical Trial Group Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906. Enoxaparin Clinical Trial Group.
29. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, . Steering Committee of the Pentasaccharide in Major Knee Surgery Study Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective hip-replacement surgery. N Engl J Med 2001, 345:1305-1310. 10.1056/NEJMoa011099, 11794149, Steering Committee of the Pentasaccharide in Major Knee Surgery Study.
30. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, . Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304. 10.1056/NEJMoa011100, 11794148, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study.
31. ENOXACAN Study Group Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997, 84:1099-1103. 10.1002/bjs.1800840817, 9278651, ENOXACAN Study Group.
32. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 IU versus 5000 XaI units in 2070 patients. Br J Surg 1995, 82:496-501. 10.1002/bjs.1800820421, 7613894.
33. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, . PEGASUS investigators Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005, 92:1212-1220. 10.1002/bjs.5154, 16175516, PEGASUS investigators.
34. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793-800. 10.1056/NEJM199909093411103, 10477777.
35. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996, 26(Suppl 2):49-56.
36. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, . THE-PRINCE Study Group Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145:614-621. 10.1067/mhj.2003.189, 12679756, THE-PRINCE Study Group.
37. Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002, 106:84-92. 10.1034/j.1600-0404.2002.01215.x, 12100367.
38. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF, . PREVAIL Investigators The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007, 369:1347-1355. 10.1016/S0140-6736(07)60633-3, 17448820, PREVAIL Investigators.
39. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, . PREVENT Medical Thromboprophylaxis Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110:874-879. 10.1161/01.CIR.0000138928.83266.24, 15289368, PREVENT Medical Thromboprophylaxis Study Group.
40. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, . ARTEMIS Investigators Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo-controlled trial. BMJ 2006, 332:325-329. 10.1136/bmj.38733.466748.7C, 1363908, 16439370, ARTEMIS Investigators.
41. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002, 162:1833-1840. 10.1001/archinte.162.16.1833, 12196081.
42. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998, 158:1525-1531. 10.1001/archinte.158.14.1525, 9679793.
43. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients undergoing total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996, 348:224-228. 10.1016/S0140-6736(96)01453-5, 8684199.
44. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996, 335:696-700. 10.1056/NEJM199609053351002, 8703168.
45. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Landon GC, Jové M, . Enoxaparin Clinical Trial Group Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001, 83-A:336-345. Enoxaparin Clinical Trial Group.
46. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, . ENOXACAN II Investigators Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002, 346:975-980. 10.1056/NEJMoa012385, 11919306, ENOXACAN II Investigators.
47. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G, Petersen AO, Siem P, Hørlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Møller JC, Rotwitt L, Christensen F, Nielsen JB, Jørgensen PS, Paaske B, Tørholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E. Efficacy and safety of prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998, 89:281-287. 10.1016/S0049-3848(98)00018-8, 9669750.
48. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997, 77:26-31.
49. Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO, Wille-Jørgensen P. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998, 164:657-663. 10.1080/110241598750005534, 9728784.
50. Eriksson BI, Lassen MR, . PENTasaccharide in HIp-FRActure Surgery Plus Investigators Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003, 163:1337-1342. 10.1001/archinte.163.11.1337, 12796070, PENTasaccharide in HIp-FRActure Surgery Plus Investigators.
51. Singelyn FJ, Verheyen CC, Piovella F, Van Aken HK, Rosencher N, . EXPERT Study Investigators. for the EXPERT study Investigators The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007, 105:1540-1547. 10.1213/01.ane.0000287677.95626.60, 18042845, EXPERT Study Investigators. for the EXPERT study Investigators.
52. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K, . Enoxaparin Clinical Trial Group Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001, 134:191-202. Enoxaparin Clinical Trial Group.
53. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994, 72:186-190.
54. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996, 76:195-199.
55. Simmoneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997, 337:663-669. 10.1056/NEJM199709043371002, 9278462.
56. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677-681. 10.1056/NEJM199603143341101, 8594425.
57. Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, Kovacs J, Kovacs MJ. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005, 165:733-738. 10.1001/archinte.165.7.733, 15824291.
58. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000, 160:181-188. 10.1001/archinte.160.2.181, 10647756.
59. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, . Matisse Investigators Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702. Matisse Investigators.
60. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, . Matisse Investigators Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867-873. Matisse Investigators.
61. Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH, . ASTH DVT Study Group Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005, 19:173-181. 10.1007/s11239-005-1848-x, 16082604, ASTH DVT Study Group.
62. Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, Laporte S. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005, 128:2203-2210. 10.1378/chest.128.4.2203, 16236875.
63. Huse DM, Cummins G, Taylor DC, Russell MW. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Am J Manag Care 2002, 8(1 Suppl):S10-16.
64. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, . Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153. 10.1056/NEJMoa025313, 12853587, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
65. Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost 2006, 12:267-276. 10.1177/1076029606291434, 16959680.
66. Jeske WP, Ackerman P, Drenth A, Walenga J, Bakhos M. Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays [abstract]. J Thromb Haemost 2007, 5(Suppl 2):P-M-647.
67. Jeske WP, Brubaker A, Hoppensteadt D, Walenga JM, Ma Q, Fareed J. Differences in the oligosaccharide composition of generic versions of enoxaparin and dalteparin [abstract]. J Thromb Haemost 2007, 5(Suppl 2):P-M-670.
68. Fareed J, Bick RL, Rao G, Goldhaber SZ, Sasahara A, Messmore HL, Happensteadt DA, Nicolaides A, . IACATH; IUA; SASAT; NATF The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products. Clin Appl Thromb Hemost 2008, 14:5-7. 10.1177/1076029607312278, 18182679, IACATH; IUA; SASAT; NATF.